Sofinnova Investments’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-456,031
| Closed | -$89.9M | – | 61 |
|
|
2026
Q1 | $89.9M | Sell |
456,031
-360,136
| -44% | -$69.4M | 3.42% | 8 |
|
|
2025
Q4 | $150M | Buy |
816,167
+404,200
| +98% | +$70.9M | 6.47% | 3 |
|
|
2025
Q3 | $63.2M | Buy |
411,967
+265,136
| +181% | +$40.1M | 3.46% | 6 |
|
|
2025
Q2 | $20.5M | Buy |
+146,831
| New | +$20.6M | 1.26% | 26 |
|
|
2025
Q1 | – | Sell |
-325,672
| Closed | -$42.7M | – | 70 |
|
|
2024
Q4 | $42.7M | Sell |
325,672
-79,031
| -20% | -$11.1M | 3.11% | 8 |
|
|
2024
Q3 | $63.1M | Buy |
404,703
+3,994
| +1% | +$645K | 5% | 4 |
|
|
2024
Q2 | $62.5M | Buy |
400,709
+102,352
| +34% | +$15.4M | 3.25% | 8 |
|
|
2024
Q1 | $40.4M | Sell |
298,357
-126,932
| -30% | -$16.8M | 2.25% | 15 |
|
|
2023
Q4 | $57.3M | Sell |
425,289
-256,129
| -38% | -$33.3M | 3.2% | 7 |
|
|
2023
Q3 | $92.3M | Sell |
681,418
-167,341
| -20% | -$22.9M | 5.82% | 3 |
|
|
2023
Q2 | $121M | Buy |
+848,759
| New | +$125M | 7.96% | 3 |
|
|
2023
Q1 | – | Sell |
-306,837
| Closed | -$41.6M | – | 56 |
|
|
2022
Q4 | $41.6M | Sell |
306,837
-44,102
| -13% | -$5.53M | 2.47% | 11 |
|
|
2022
Q3 | $38.5M | Buy |
350,939
+192,759
| +122% | +$24.5M | 2.24% | 10 |
|
|
2022
Q2 | $20.9M | Sell |
158,180
-118,772
| -43% | -$15.6M | 1.74% | 16 |
|
|
2022
Q1 | $36.7M | Buy |
+276,952
| New | +$33.2M | 2.79% | 8 |
|
|
2021
Q4 | – | Sell |
-564,136
| Closed | -$67.8M | – | 73 |
|
|
2021
Q3 | $67.8M | Buy |
564,136
+84,320
| +18% | +$9.82M | 4.01% | 5 |
|
|
2021
Q2 | $57.5M | Sell |
479,816
-38,050
| -7% | -$4.17M | 3.31% | 6 |
|
|
2021
Q1 | $51.5M | Buy |
517,866
+96,566
| +23% | +$9.71M | 3.1% | 6 |
|
|
2020
Q4 | $42.1M | Buy |
+421,300
| New | +$44.6M | 2.51% | 7 |
|
|
2019
Q2 | – | Sell |
-130,789
| Closed | -$10.6M | – | 72 |
|
|
2019
Q1 | $10.6M | Sell |
130,789
-27,375
| -17% | -$2.16M | 1.02% | 20 |
|
|
2018
Q4 | $12M | Buy |
158,164
+37,860
| +31% | +$2.96M | 1.5% | 17 |
|
|
2018
Q3 | $9.52M | Sell |
120,304
-44,596
| -27% | -$3.37M | 0.85% | 22 |
|
|
2018
Q2 | $11.6M | Buy |
164,900
+153,984
| +1,411% | +$11.1M | 1.31% | 19 |
|
|
2018
Q1 | $763K | Buy |
+10,916
| New | +$756K | 0.13% | 23 |
|
Other funds holding AZN
EP
IA
Sofinnova Investments's AZN Position: Q2 2026 in Review
Sofinnova Investments sold out of AstraZeneca (AZN) in Q2 2026, closing a stake of 456,031 shares — an estimated $89.9M sold.
Sofinnova Investments first reported a position in AZN in Q1 2018 and held it in 24 quarters. The position peaked at $150M in Q4 2025. 1,503 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- Sofinnova Investments reported no remaining AstraZeneca position as of Q2 2026 after selling out during the quarter.
- Sofinnova Investments sold 456,031 AstraZeneca shares in Q2 2026, an estimated $89.9M.
- Sofinnova Investments first reported a position in AstraZeneca in Q1 2018 and held it in 24 quarters.
- Sofinnova Investments's AstraZeneca position peaked at $150M in Q4 2025.
- 1,503 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on Sofinnova Investments's 13F filing for Q2 2026, filed 14 Aug 2026.